Expression and Prognostic Value of PIK3CA, VEGF, IL-8, IL-10, and RIP2 in Diffuse Large B-Cell Lymphoma

Table 2

Regression analysis of the univariate Cox proportional hazard model for overall survival.

Clinical features	b	Sb	Wald χ^2	HR	95% CI	value
Age (years)
<60 vs. ≥60	0.619	0.567	1.201	1.867	0.603–5.672	0.269
Gender
Male vs. female	−0.287	0.503	0.846	0.631	0.218–1.654	0.347
Ann Arbor Stage
I, II vs. III, IV	1.376	0.529	7.389	4.302	1.403–11.098	0.004
B symptoms
Presence vs. absence	0.417	0.387	1.081	1.509	0.683–3.201	0.287
Extranodal site
≤1 vs. >1	0.821	0.267	4.762	1.573	1.013–2.761	<0.001
Serum LDH level (U/L)
<245 vs. ≥245	0.298	0.331	2.786	1.545	0.893–2.198	0.028
IPI scores
0–2 vs. 3–5	−0.401	0.603	0.488	0.675	0.209–2.061	0.453
ECOG scores
0-1 vs. ≥2	1.109	0.434	7.135	3.297	1.309–8.076	0.003
Bone marrow involvement
Presence vs. absence	0.351	0.292	3.091	1.298	1.009–1.765	0.025
Extranodal involvement
Presence vs. absence	0.318	0.102	8.659	1.342	1.201–1.612	<0.001
Hans
GCB vs. non-GCB	0.371	0.529	0.469	1.429	0.499–4.091	0.489
VEGF level
Low vs. high	0.221	0.318	0.352	1.026	0.738–1.329	0.008
PIK3CA
Negative vs. positive	1.731	0.857	2.372	5.321	1.096–7.438	<0.001
IL-8 level
Low vs. high	1.903	0.937	9.682	6.048	4.378–12.981	<0.001
IL-10 level
Low vs. high	1.298	0.518	5.703	3.462	1.254–9.028	0.013
RIP2
Negative vs. positive	1.176	0.706	7.902	3.189	1.651–5.034	0.016

DLBCL, diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; GCB, germinal center B-cell; IPI, international prognostic index; ECOG, eastern cooperative oncology group; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; VEGF, vascular endothelial growth factor; IL, interleukin; RIP2, receptor-interacting protein-2; HR, hazard ratio; CI, confidence interval.